Sep 17, 2020 / 05:15PM GMT
David Reed Risinger - Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst
Thank you. So good afternoon, everyone, and thank you very much for joining our session with Bristol-Myers. My name is Dave Risinger. I cover both major and specialty pharmaceuticals at Morgan Stanley.
Before we get started, I need to refer you to a disclaimer. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. It's not for members of the press. If you're a member the press, please disconnect and reach out separately. For important disclosures, please see www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.
So I wanted to welcome Giovanni Caforio, who is the CEO and Chairman of Bristol-Myers. He became CEO in 2015, originally joined Bristol in 2000 as a VP and General Manager. He took on positions of increasing responsibility, eventually
Bristol-Myers Squibb Co at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers